Quellis Biosciences nabs $17 mln Series A
Boston-based Quellis Biosciences Inc., an emerging biopharmaceutical company focused on treating serious rare diseases, has raised $17 million in Series A financing.
Boston-based Quellis Biosciences Inc., an emerging biopharmaceutical company focused on treating serious rare diseases, has raised $17 million in Series A financing.
Copyright PEI Media
Not for publication, email or dissemination